British Hospital

About: British Hospital is a healthcare organization based out in Montevideo, Uruguay. It is known for research contribution in the topics: Population & Lung cancer. The organization has 445 authors who have published 358 publications receiving 7878 citations. The organization is also known as: British Hospital.

A New Parallelizable Deformation Method - Automatic Comparision between Foot and Last.

Abstract: This document shows the research project developed by the Computer Graphics and Vision Group in collaboration with Inescop. The main objective of this project is to define a new methodology to design shoes exactly adapted to the shape foot. The system proposed is based on a biomechanical anatomical structure of the foot and using a deformable shape. Using with several joints adapted the different foots to different shoe last evaluating the error between the surfaces. The system is automatic driven in the selection of significant foot points. We consider several anthropometrical parts of the foot in order to apply the deformations of the shape with different axis. The proposed system is implemented in software. An associated Application Programming Interface (API) is also developed for commercial use of the system. Also the results presented evaluate the error between deformations.

An individual patient data (IPD) meta-analysis of the impact of thrombocytosis (?plts) on overall survival (OS) whilst using an intermittent chemotherapy (iCTx) strategy in advanced colorectal cancer (aCRC).

Abstract: e15044Background: iCTx in pts with aCRC offers potential for improvement in QoL. The COIN trial is the largest study to compare iCTx v. continuous strategies in aCRC, a pre-specified subgroup analy...

Long-Term Response and Possible Cure of Patients With B-Cell Malignancies With Dose-Escalated Rituximab.

Abstract: Rituximab (R), a chimeric monoclonal antibody targeting CD20 antigen on B-cells, has become a standard of care in the treatment of B-cell malignancies, most often in conjunction with cytotoxic chemotherapy. Activity has been demonstrated in many subtypes of B-cell lymphoma, including diffuse large cell lymphoma, follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), lymphocyte-predominant Hodgkin lymphoma, and Waldenstrom macroglobulinemia (WM). Additionally, dose escalation of R as a single agent has demonstrated improved activity in previously treated/poor prognosis CLL. We present 4 cases of B-cell malignancy (2 CLL variants/MCL, 1 FL, 1 WM) who received dose-escalated R as a single agent and achieved complete response (3 patients) and stable disease/partial response (1 patient) of 6.5+ to 15+ years duration. They have been off treatment for 6.5+ to 15+ years. Toxicity was minimal, with initial infusion reactions similar to those observed with standard dose infusions. There were no serious treatment-related adverse events or infections. Dose escalated R as a single agent may possibly be curative for some patients with B-cell malignancies, unlike the standard empiric dose of 375 mg/m2, and deserves further study.